Drugs / Ixovex-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06549946 | Dec 2024 → Jan 2027 expected | head and neck cancer | Psivac Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-08 | Psivac Ltd | PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1 psivac.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ixovex-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06549946 ↗ |
| Route | Other | “intratumoural (IT) injection” NCT06549946 ↗ |